Leo Pharma plans to acquire dermatology biotech Timber Pharmaceuticals, which is developing a treatment for a rare, genetic skin disease.
The privately held Danish biopharma will pay $14 million upfront, and Timber can receive up to another $22 million in milestone payments, bringing the transaction’s total potential value to $36 million. The deal is expected to close in the fourth quarter of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.